- Home
- PCVX vs MBLY Comparison
PCVX vs MBLY Comparison
Compare PCVX & MBLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PCVX | MBLY |
|---|---|---|
| Founded | 2013 | 1999 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 7.3B |
| IPO Year | 2020 | 2022 |
Fundamental Metrics
Financial Performance| Metric | PCVX | MBLY |
|---|---|---|
| Price | $60.64 | $5.66 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 24 |
| Target Price | ★ $117.30 | $9.76 |
| AVG Volume (30 Days) | 3.7M | ★ 6.3M |
| Earning Date | 11-13-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 87.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,894,000,000.00 |
| Revenue This Year | N/A | $6.21 |
| Revenue Next Year | N/A | $8.21 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 14.51 |
| 52 Week Low | $39.87 | $5.76 |
| 52 Week High | $90.75 | $14.33 |
Technical Indicators
Market Signals| Indicator | PCVX | MBLY |
|---|---|---|
| Relative Strength Index (RSI) | 46.07 | 27.65 |
| Support Level | $58.85 | N/A |
| Resistance Level | $63.08 | $9.55 |
| Average True Range (ATR) | 2.87 | 0.38 |
| MACD | -0.55 | -0.09 |
| Stochastic Oscillator | 15.18 | 4.04 |
Price Performance
Historical ComparisonAbout PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
About MBLY Mobileye Global Inc.
Mobileye Global Inc engages in the development and deployment of ADAS and autonomous driving technologies and solutions. It is building a portfolio of end-to-end ADAS and autonomous driving solutions to provide the capabilities needed for the future of autonomous driving, leveraging a comprehensive suite of purpose-built software and hardware technologies. The company's reportable operating segment are Mobileye and Moovit. The solutions provided by the company are: Driver Assist, Cloud-Enhanced Driver Assist, Mobileye SuperVision Lite, Mobileye SuperVision, Mobileye Chauffeur, Mobileye Drive, Self-Driving System & Vehicles. It derives maximum revenue from Mobileye Segment.